Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 61Stomach Neoplasms 10HER2-positive Breast Cancer 7Colorectal Neoplasms 6Neoplasm Metastasis 5Inflammatory Breast Neoplasms 3Breast Diseases 3Brain Neoplasms 3Pathologic Complete Response 2Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cardiotoxicity 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Relapsed Pediatric Solid Tumor 1Pancreatic Neoplasms 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Invasive Breast Cancer 1Intestinal Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1HER2-positive 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Gastric Cancer 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Feasibility 1

Interventions

Trastuzumab 2toripalimab 1pyrotinib 1Vinblastine 1Transurethral Resection of Bladder 1Thalidomide 1TP protocol 1Sodium Chloride 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neoadjuvant Therapy 1Metformin 1Magnetic Resonance Imaging 1Immunohistochemistry 1Esophagectomy 1Endoscopy 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Diffusion Magnetic Resonance Imaging 1Dexamethasone 1Decitabine 1Cytarabine 1Cisplatin 1Chemoradiotherapy 1Cell-Free Nucleic Acids 1Carboplatin 1Bortezomib 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Pathologic Complete Response × Trastuzumab × Clear all
NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
65 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT02059876 2014-02-12

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

Guangdong Provincial People's Hospital

Phase 2 Unknown
60 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡